** Shares of life sciences firm Danaher DHR.N fall 5.2% to $235 premarket
** DHR posts Q4 EPS of $2.14, below analysts' estimates of $2.16, according to LSEG data, due to weak demand from biotech and pharmaceutical clients
** Forecasts Q1 2025 adjusted core revenue to "decline low-single digits year-over-year"
** DHR's diagnostics business posts sales of $2.64 bln vs. analysts' est. of $2.55 bln - LSEG
** Life sciences unit posts sales of $2.03 bln vs. analysts' est. of $1.96 bln - LSEG
** DHR reports Q4 sales of $6.54 bln vs. analysts' est. of $6.43 bln - LSEG
** Forecasts FY 2025 adjusted core rev. to increase about 3% year-over-year
** DHR fell 2.2$ in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.